FDA Clears Grifols' Application for Dry Eye Disease Treatment

Moody's Ratings has improved the corporate family rating (CFR) of Grifols from 'B3' to 'B2' and the default probability rating (PDR) from 'B3' to 'B2-PD', while the outlook remains 'positive'. Consequently, the US agency has improved the rating of the secured senior instruments with support issued by Grifols, Grifols World Wide Operations Ltd. and Grifols World Wide Operations USA, Inc. to 'B1'. Simultaneously, it has improved the rating of the …

The rating agency Moody's raises Grifols' credit rating from B3 to B2 to the good results scored by the blood product manufacturer and his...

FDA clears Grifols' Investigational New Drug application for immunoglobulin drops for the treatment of DED

ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

FDA clears Grifols' application for dry eye disease treatment

The US FDA has cleared Grifols' investigational new drug (IND) application to commence a Phase II trial of GRF312 Ophthalmic SolutionThe post FDA clears Grifols’ application for dry eye disease treatment appeared first on Clinical Trials Arena.

In addition, this advance represents a possible new therapeutic approach to dry eye disease. Dry eye disease is a common inflammatory condition that affects more than 100 million people around the world. It is characterized by insufficient moisture on the outer surface of the eye, which, in the most serious cases, can cause permanent damage to vision. The study will analyze the safety, tolerability and efficacy of this eye drops in 100 patients …